ArticlePharmacognosy research
Oleanolic Acid Prevents Increase in Blood Pressure and Nephrotoxicity in Nitric Oxide Dependent Type of Hypertension in Rats.
Article in Pharmacognosy research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03886597 (Table Olives Nutritional Intervention), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Table Olives Nutritional Intervention: Pharmacokinetics of Polyphenols and Pentacyclic Triterpenes and Assessment of Antioxidant, Cardiovascular and Anti-inflammatory Biomarkers
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Traditional Chinese medicine method of tonifying kidney for hypertension: Clinical evidence and molecular mechanisms.Frontiers in cardiovascular medicine · 2022Pooled it
- Evaluation of the Effect of Pistacia atlantica Oleoresin on Blood Sugar, Pressure and Lipids in Patients With Type 2 Diabetes: A Single-Blind, Placebo-Controlled Trial.Endocrinology, diabetes & metabolism · 2024Trial
- Unlocking the Potential of Oleanolic Acid: Integrating Pharmacological Insights and Advancements in Delivery Systems.Pharmaceutics · 2024Review
- The Effect and Mechanism of Oleanolic Acid in the Treatment of Metabolic Syndrome and Related Cardiovascular Diseases.Molecules (Basel, Switzerland) · 2024Review
- The cardioprotective potential of selected species of mistletoe.Frontiers in pharmacology · 2024Review
- Pulegone Prevents Hypertension through Activation of Muscarinic Receptors and Cyclooxygenase Pathway in L-NAME-Induced Hypertensive Rats.Cardiovascular therapeutics · 2023Article
- Review
- Antihypertensive activity of oleanolic acid is mediated via downregulation of secretory phospholipase A2 and fatty acid synthase in spontaneously hypertensive rats.International journal of molecular medicine · 2020Article
- Exploration of the effects of goose TCs on GCs at different follicular stages using a co-culture model.Bioscience reports · 2020Article
- Biological activity of mistletoe: in vitro and in vivo studies and mechanisms of action.Archives of pharmacal research · 2020Review
- Epigenetics/epigenomics of triterpenoids in cancer prevention and in health.Biochemical pharmacology · 2020Review
- Modulation of Lipid Transport and Adipose Tissue Deposition by Small Lipophilic Compounds.Frontiers in cell and developmental biology · 2020Review
- Potential Protective Effect of Oleanolic Acid on the Components of Metabolic Syndrome: A Systematic Review.Journal of clinical medicine · 2019Review
- Oleanolic Acid and Its Derivatives: Biological Activities and Therapeutic Potential in Chronic Diseases.Molecules (Basel, Switzerland) · 2017Review
- Cardioprotective Effects ofJournal of evidence-based integrative medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, we have reported antihypertensive activity of oleanolic acid (OA) in glucocorticoid-induced hypertension with restoration of nitric oxide (NO) level. However, the involvement of NO-releasing action of OA was unclear.
objectiveTo explore antihypertensive activity of OA in N(ω)-nitro-L-arginine methyl ester (L-NAME) hypertensive rats wherein NO is completely blocked, which would allow exploring the possibility of involvement of NO-releasing action of OA. MATERIALS AND
methodsFive groups of rats were investigated as normal control, L-NAME (40 mg/kg/day), L-NAME + enalapril (15 mg/kg/day), L-NAME + l-arginine (100 mg/kg/day), and L-NAME + OA (60 mg/kg/day) for 4 weeks. The systolic blood pressure, body weight, and heart rate were measured weekly for 4 weeks. Serum nitrate/nitrite (NOx) level, urine electrolytes concentration, cardiac mass index, and serum creatinine level were determined followed by organ histopathology.
resultsOA and enalapril delayed the rise in blood pleasure following L-NAME administration. Decreased serum NOx level was not significantly increased with any of the treatment. OA produced a small, though nonsignificant, increase in the NOx level. L-NAME administration did not affect cardiac mass index. There was an increase in serum creatinine upon L-NAME administration which was prevented by OA. Decreased urine volume, urine sodium and potassium were reversed by OA.
conclusionThese results suggest that the antihypertensive effect of OA in L-NAME hypertension is due to diuresis and nephroprotection. However, OA has nonsignificantly affected the NO levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.